Status Change

Chia Tai Tianqing opens China trial testing adalimumab in pediatric uveitis

The Phase 4 study measures time to treatment failure in children with non-infectious uveitis, a setting where adalimumab already has one completed Chinese cohort behind it.

By AppliedXLJuly 15, 2026Trial NCT07663331

Executive Summary

Chia Tai Tianqing Pharmaceutical Group has opened enrollment in a pediatric extension of its adalimumab program in non-infectious uveitis, moving the study from planning into active recruitment.
The trial measures how quickly treated children relapse over six months, a bar the same drug has already been tested against in an adult Chinese cohort and in a placebo-controlled study abroad.
Adalimumab enters a field with limited direct competition on its own target in this disease, while other mechanisms are being tested in parallel for the broader uveitis population.
The event itself is procedural, but it puts a multi-year clock on the next disclosure that will show whether the pediatric relapse rate tracks the drug's adult and other-indication track record.

The status change

NCT07663331 moved from Not yet recruiting to Recruiting on July 15, 2026, after adding its protocol details on June 23. The multicenter, open-label study (no control group) will enroll 30 children across sites in China, testing Chia Tai Tianqing's adalimumab, sold under the Tebiovio brand, in patients with active non-infectious intermediate, posterior, or panuveitis who require systemic corticosteroids at baseline. The primary completion date is set for February 1, 2028, roughly 19 months from the start of recruitment. NCT07663331+1

The endpoint bar

The primary endpoint is time to treatment failure, measured at week 6 and between weeks 6 and 24. Secondary measures track visual acuity, anterior chamber and vitreous inflammation grading, corticosteroid tapering to 7.5 mg or below, and adverse event rates through week 24. As an open-label, single-arm study without a placebo comparator, the trial is built to characterize adalimumab's effect and safety in a pediatric population rather than to establish superiority over another treatment. NCT07663331

Same-drug precedent

Adalimumab already has a track record in this exact indication: a placebo-controlled Phase 3 trial in active uveitis enrolled 239 patients and completed in 2014, and Chia Tai Tianqing itself completed an 87-patient Phase 4 study of adalimumab in Chinese adults with non-infectious intermediate, posterior, or panuveitis in 2024. This new study extends that same drug and same disease population into children, rather than testing a new mechanism.

The competitive field

Within TNF-alpha-targeted therapy for non-infectious uveitis, the trial has no other adalimumab or TNF-alpha competitor actively enrolling in China for this indication. The broader uveitis field includes Priovant Therapeutics' TYK2 inhibitor brepocitinib in a Phase 3 trial nearing a September 2026 completion, ANI Pharmaceuticals' fluocinolone acetonide implant, and other non-TNF mechanisms such as ACELYRIN's izokibep, an IL-17A-targeted therapy. TNF-alpha as a target has broader momentum outside uveitis, with 34 recent trials against 255 older ones, indicating overall activity in the target class has slowed even as adalimumab remains established across rheumatoid arthritis, Crohn's disease, and psoriasis.

Sponsor track record

Chia Tai Tianqing has completed 75 of 105 trials with a documented outcome, a 71% completion rate. Across its broader pipeline of 382 trials, 65 are currently recruiting and 30 have been terminated. The company's registry history for this specific trial shows a single status change and no protocol amendments beyond the recruitment update, consistent with a stable early-stage launch. NCT07663331

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.